Anika Therapeutics, Inc. (ANIK)

NasdaqGS • Currently down 0.28 (-1.36%) in today's trading session

1 member of Congress has disclosed 18 trades in Anika Therapeutics, Inc. (ANIK) via STOCK Act filings. The most recent disclosure was a purchase by Tom Malinowski on 2 March 2020. Aggregate disclosed activity totals roughly $303.5K in purchases and $48K in sales (midpoint estimates from bracketed disclosure amounts).

Anika Therapeutics, Inc. is currently trading at $20.25, positioned at 81% of its 52-week range ($8.67 – $22.88).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$20.25
24h Change
-0.28 (-1.36%)
52 Week Range
$8.67–$22.88
View on NASDAQ

Anika Therapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ANIK

Select to highlight on chart
5 transactions
Compliance: 44%
Tom Malinowski2 Mar 20205 Mar 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski2 Mar 202026 Aug 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski2 Mar 202030 Jul 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski28 Feb 202026 Aug 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski28 Feb 202026 Aug 2021PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$271.01M

Volume

93.54K

Beta

0.21

P/E Ratio

41.33

Fundamentals

EPS

$0.49

Div. Yield

-

Open

$20.46

Day Range

$20.12 – $20.51

Company Information

Sector
Healthcare
Industry
Medical - Specialties
Exchange
NASDAQ · USD
Country
US
CEO
Stephen D. Griffin
IPO Date
1993-05-03

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain manag...

Earnings

Next Report

Q3 2026

4 Nov

EPS Est.

$0.42

Rev. Est.

$29.4M

Days Until

20

Recent Quarters

Q2 202629 Jul
EPS$0.42
Beat 1300.0%
Q1 202629 Apr
EPS$0.27
Beat 485.7%
Q4 202526 Feb
EPS$0.31
Beat 348.0%
Q3 20255 Nov
EPS$0.04
Beat 100.0%
Q2 202530 Jul
EPS$-0.13
Beat 0.0%
Q1 20259 May
EPS$-0.06
Miss 166.7%
Q4 202412 Mar
EPS$-0.03
Miss 200.0%
Q3 202431 Oct
EPS$-0.25
Miss 183.3%
Q2 20248 Aug
EPS$0.17
Miss 26.1%
Q1 20248 May
EPS$-0.31
Miss 63.2%
Q4 202313 Mar
EPS$-4.30
Miss 1553.8%
Q3 20232 Nov
EPS$-0.45
Miss 36.4%
Q2 20238 Aug
EPS$-0.19
Beat 44.1%
Q1 20239 May
EPS$-0.71
Miss 136.7%
Q4 20226 Mar
EPS$-0.34
Miss 54.5%
Q3 20228 Nov
EPS$-0.29
Miss 20.8%
Q2 20223 Aug
EPS$-0.20
Beat 23.1%
Q1 20225 May
EPS$-0.20
Beat 35.5%
Q4 20218 Mar
EPS$-0.40
Miss 60.0%
Q3 20214 Nov
EPS$0.04
Beat 119.0%
Q2 20215 Aug
EPS$0.45
Beat 400.0%
Q1 20216 May
EPS$0.20
Beat 266.7%
Q4 20204 Mar
EPS$-1.10
Miss 1000.0%
Q3 20204 Nov
EPS$-0.45
Miss 462.5%
Q2 202030 Jul
EPS$0.09
Beat 142.9%
Q1 20207 May
EPS$0.45
Beat 12.5%
Q4 201920 Feb
EPS$0.43
Beat 4.9%
Q3 201924 Oct
EPS$0.64
Beat 64.1%
Q2 201924 Jul
EPS$0.68
Beat 74.4%
Q1 20192 May
EPS$0.31
Beat 63.2%
Q4 201821 Feb
EPS$0.54
Beat 63.6%
Q3 201824 Oct
EPS$0.53
Beat 71.0%
Q2 201825 Jul
EPS$0.68
Beat 106.1%
Q1 20182 May
EPS$0.11
Miss 56.0%
Q4 201721 Feb
EPS$0.38
Miss 7.3%
Q3 201725 Oct
EPS$0.46
Beat 2.2%
Q2 201726 Jul
EPS$0.76
Beat 72.7%
Q1 20173 May
EPS$0.37
Miss 2.6%
Q4 201615 Feb
EPS$0.54
Beat 1.9%
Q3 201626 Oct
EPS$0.59
Beat 25.5%
Q2 201627 Jul
EPS$0.57
Beat 29.6%
Q1 201627 Apr
EPS$0.45
Beat 60.7%
Q4 201524 Feb
EPS$0.72
Beat 20.0%
Q3 201528 Oct
EPS$0.55
Beat 57.1%
Q2 201529 Jul
EPS$0.51
Beat 50.0%
Q1 201528 Apr
EPS$0.23
Beat 9.5%
Q4 201425 Feb
EPS$0.51
Beat 6.3%
Q3 201429 Oct
EPS$0.40
Beat 21.2%
Q2 201430 Jul
EPS$0.60
Beat 5.3%
Q1 201429 Apr
EPS$0.97
Beat 288.0%
Q4 201326 Feb
EPS$0.44
Beat 4.8%
Q3 201330 Oct
EPS$0.33
Beat 106.3%
Q2 201331 Jul
EPS$0.40
Beat 73.9%
Q1 20131 May
EPS$0.20
Beat 17.6%
Q4 201227 Feb
EPS$0.42
Beat 75.0%
Q3 201230 Oct
EPS$0.12
Miss 29.4%
Q2 20121 Aug
EPS$0.26
Beat 62.5%
Q1 20123 May
EPS$0.14
Miss 17.6%
Q4 201129 Feb
EPS$0.21
Beat 61.5%
Q3 20114 Nov
EPS$0.22
Q3 20112 Nov
EPS$0.22
Beat 100.0%
Q1 20116 May
EPS$0.02
Q4 201016 Mar
EPS$0.10
Q3 20109 Nov
EPS$0.09
Q2 20109 Aug
EPS$0.08
Q1 201010 May
EPS$0.05
Q4 200916 Mar
EPS$0.05
Q3 200927 Oct
EPS$0.13
Beat 30.0%
Q2 200922 Jul
EPS$0.08
Beat 0.0%
Q1 200929 Apr
EPS$0.05
Miss 44.4%
Q4 20085 Mar
EPS$0.10
Miss 23.1%
Q3 20083 Nov
EPS$0.10
Miss 9.1%
Q2 200822 Jul
EPS$0.07
Beat 16.7%
Q1 200830 Apr
EPS$0.05
Miss 44.4%
Q4 20075 Mar
EPS$0.15
Beat 7.1%
Q3 20075 Nov
EPS$0.16
Beat 6.7%
Q2 200724 Jul
EPS$0.12
Beat 0.0%
Q1 200726 Apr
EPS$0.11
Beat 0.0%
Q4 200628 Feb
EPS$0.09
Miss 18.2%
Q3 200624 Oct
EPS$0.12
Beat 9.1%
Q2 200624 Jul
EPS$0.12
Beat 33.3%
Q1 200625 Apr
EPS$0.08
Beat 0.0%
Q4 20052 Mar
EPS$0.07
Beat 100.0%
Q3 200518 Oct
EPS$0.22
Beat 120.0%
Q2 200527 Jul
EPS$0.12
Beat 20.0%
Q1 200527 Apr
EPS$0.10
Beat 25.0%
Q4 200423 Feb
EPS$0.15
Beat 150.0%
Q3 200429 Oct
EPS$0.08
Beat 33.3%
Q2 20046 Aug
EPS$0.07
Beat 40.0%
Q1 200417 May
EPS$0.69
Q1 200429 Apr
EPS$0.07
Beat 75.0%
Q3 200314 Nov
EPS$0.04
Q2 200314 Aug
EPS$-0.01
Q1 200315 May
EPS$-0.03
Q4 200227 Mar
EPS$0.07
Q3 200213 Nov
EPS$-0.07
Q2 200214 Aug
EPS$-0.12
Q1 200215 May
EPS$-0.18
Q4 200128 Mar
EPS$-0.05
Q3 200114 Nov
EPS$-0.13
Q2 200114 Aug
EPS$-0.27
Q1 200115 May
EPS$-0.23
Q1 20012 Apr
EPS$0.24
Q3 200014 Nov
EPS$-0.14
Q2 200014 Aug
EPS$-0.02
Q1 200027 Apr
EPS$-0.06
Q4 199915 Mar
EPS$0.04
Beat 100.0%
Q3 199921 Oct
EPS-
Q2 199922 Jul
EPS$0.04
Beat 100.0%
Q1 199921 Apr
EPS$0.03
Beat 20.0%
Q4 199825 Feb
EPS$0.07
Miss 30.0%
Q3 199822 Oct
EPS$0.07
Beat 40.0%
Q2 199821 Jul
EPS$0.22
Beat 340.0%
Q1 199815 Apr
EPS$0.06
Beat 0.0%
Q4 199724 Feb
EPS$0.35
Miss 14.6%
Q3 199723 Oct
EPS$-0.05
Miss 266.6%
Q2 199721 Aug
EPS$0.05
Beat 150.0%
Q2 199710 Jul
EPS$0.04
Beat 100.0%
Q4 199614 Jan
EPS$-0.19
Q2 199631 Aug
EPS$-0.19
Q2 199615 Jul
EPS$-0.12
Q4 199529 Feb
EPS$-0.26
Q3 199530 Nov
EPS$-0.16
Q2 199531 Aug
EPS$-0.29
Q1 199531 May
EPS$-0.14
Q4 199428 Feb
EPS$-0.06
Q3 199430 Nov
EPS$-0.14
Q2 199431 Aug
EPS$-0.17
Q1 199431 May
EPS$-0.17
Q4 199328 Feb
EPS$-0.07
Q3 199330 Nov
EPS$-0.04
Q2 199331 Aug
EPS$-0.20
Q1 199331 May
EPS$-0.14

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

CELC

Celcuity Inc.

47
$59.90-3.29 (-5.21%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

PCRX

Pacira BioSciences, Inc.

47
$36.40+0.09 (+0.25%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

TSLA

Tesla, Inc.

20
$367.16-8.07 (-2.15%)
Consumer Cyclical
Held by same politician
Significant holdings value
1 politician
View Stock

Frequently Asked Questions about ANIK

Which members of Congress have traded ANIK?
1 member of Congress has disclosed 18 trade in Anika Therapeutics, Inc. (ANIK) under the STOCK Act: Tom Malinowski.
When was ANIK most recently disclosed by Congress?
The most recent ANIK disclosure was a purchase by Tom Malinowski on 2 March 2020.
What is the total disclosed congressional trading volume for ANIK?
Members of Congress have disclosed approximately $303.5K in ANIK purchases and $48K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ANIK?
This ANIK page updates as soon as new STOCK Act disclosures are filed for Anika Therapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.